pharmaphorum

MARCH 7, 2024

Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.

83

83

World of DTC Marketing

MARCH 14, 2022

It’s not only getting harder for small biotechs to find funding; too many have scaled up operations by adding employees too quickly, forcing them to lay off people as the path to new drug approvals gets more complicated. Some VCs require small biotechs to have lower expenses, including employee payrolls. I hope patients can wait.

FDA 200

FDA Medical Pharma Media 200

Pharmaceutical Commerce

FEBRUARY 4, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Prescription 69

Prescription Distribution Biopharma Marketing 69

Pharmaceutical Commerce

APRIL 2, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Distribution 52

Distribution Biopharma Pharma Marketing 52

PharmaVoice

MARCH 26, 2024

After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.

52

52

European Pharmaceutical Review

MAY 23, 2023

New research by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20 percent of European biotech companies are now headquartered in Switzerland. Sixty three out of a total of 265 companies settling in Switzerland were biotechs. Why are European biotech’s choosing Switzerland?

Biopharma 107

Biopharma Government Pharma Medicine 107

World of DTC Marketing

DECEMBER 17, 2021

As biopharmadive recently, “some of the biggest pharmaceutical companies, sitting on large and growing sums of cash, are funneling those funds into major share buyback programs and acquisitions of smaller biotech companies. As one person told me, “Rich, it’s becoming big business and all about the balance sheet.”

Pharma 209

Pharma Pharmaceutical Sales Patients 209

PharmaTech

APRIL 2, 2023

A growing proportion of drugs in the development pipeline nowadays start out life at small biotech companies, rather than big pharma businesses. While this means the biotechs are taking on more risk, they will also reap greater rewards in the event of success.

Pharma 91

Pharma Management Pharmaceutical 91

Pharmaceutical Technology

MAY 9, 2023

Baxter International has signed a definitive agreement to sell its BioPharma Solutions (BPS) business to private equity investor Advent International and growth investor Warburg Pincus, in a deal valued at $4.25bn in cash. The business will offer services from clinical research to commercial deployment for clients.

Manufacturing 97

Manufacturing Biopharma Pharma Healthcare 97

MedCity News

JUNE 26, 2022

For small biotech companies that are always raising money, business development is a critical next step. Joining with a credible partner goes a long way in validating technology and platforms and gives small biotech companies the runway needed to grow.

Biopharma 97

Biopharma 97

World of DTC Marketing

AUGUST 29, 2022

A sales representative for a biotech company shared information with oncologists about patients’ attitudes towards treatment options, including the company’s brand. At a recent online seminar, a leading biotech company had over 200 oncologists discuss “helping patients understand their treatment.”

Side effects 203

Side effects Physicians Insurance Marketing 203

MedCity News

OCTOBER 4, 2022

Alban de La Sablière, global head of partnering at Sanofi for the past six years, has joined artificial intelligence biotech Owkin as its first chief business officer. In addition to finding more business partnerships, de La Sablière will also oversee expansion of Owkin’s internal drug and diagnostics pipeline.

Pharma 95

Pharma Biopharma 95

World of DTC Marketing

JANUARY 10, 2022

Pharma companies are flush with cash and looking to make deals, but there are still a lot of small biotech companies that don’t have enough money to launch their products entirely. For many of these small biotech companies, the restrictive costs are the launch costs. appeared first on World of DTC Marketing.com.

Food and Drug Administration 213

Food and Drug Administration Pharma Marketing Food 213

Pharmaceutical Commerce

JANUARY 23, 2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

Distribution 52

Distribution Biopharma Manufacturing Marketing 52

pharmaphorum

JANUARY 9, 2023

We’re preparing to start JP Morgan week with a busy day Monday, with day 1 of the Informa Biotech Showcase, including a dedicated mini-event on Cell and Gene Therapy in the morning. Then in the evening, we’ll be at STAT@JPM for presentations by event sponsor GSK as well as the guest of honour: FDA Commissioner Robert Califf.

FDA 115

FDA Healthcare Healthcare 115

MedCity News

NOVEMBER 2, 2022

The once high-flying biotech is now exploring options that could include a sale of the business or a merger with another company. Rubius Therapeutics was unable to secure financing to carry out its pivot to a new manufacturing process for its red blood cell-based cell therapies.

Manufacturing 102

Manufacturing Sales Biopharma Pharma 102

Eversana Intouch

NOVEMBER 20, 2023

In the rapidly changing landscape of global markets, staying ahead of the curve is crucial for businesses aiming to expand and thrive. Pharma/Biotech companies will continue to tailor their market access strategies locally to maximize patient outcomes and drive commercial value.

Marketing 90

Marketing Healthcare Healthcare Pharma 90

PM360

DECEMBER 20, 2023

Earlier this year, EY reported that a significant proportion of biotechs were set to run out of funds within two years and the current outlook makes that a real concern to many in the industry. However, with many biotechs running out of road, the question is whether they can hang on for long enough for a deal to be done.

Biopharma 111

Biopharma Pharma Marketing Management 111

World of DTC Marketing

MAY 3, 2022

Bio­gen an­nounced that CEO Michel Vounatsos is be­ing re­placed as the big biotech un­der­goes a re­struc­tur­ing of the pipeline. They became a big pharma company and lost some of the people who made Biogen such great biotech. Business can be cruel in its lessons. From the beginning, Aduhelm was doomed to fail.

Side effects 207

Side effects FDA Media Pharma 207

Pharmaceutical Technology

APRIL 17, 2023

NKGen Biotech, a clinical-stage natural killer (NK) cell therapy firm, has signed a definitive agreement to combine its business operations with Graf Acquisition. NKGen Biotech will become a publicly traded company, while Graf will be rebranded as NKGen Biotech.

Patients 98

Patients Leads Pharmaceutical Marketing 98

World of DTC Marketing

FEBRUARY 25, 2022

It was a move, in their minds, from fast-moving biotech to a bureaucratic, slow-moving big pharma company. Biotech company cultures are different because they have a culture of empowerment and getting it done. There is no doubt that the employees of Celgene were not happy with the BMS acquisition.

Food and Drug Administration 216

Food and Drug Administration Sales pitches Pharma Sales 216

Pharmaceutical Technology

JULY 25, 2023

Partnerships, mergers, business combinations, and acquisitions could all be on the horizon for the biotech.

52

52

Pharmaceutical Technology

JULY 6, 2022

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7.

Marketing 129

Marketing Biopharma Pharma Retail 129

pharmaphorum

AUGUST 30, 2022

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its therapeutic focus further into hormonal disorders. million ($57 million), a 144% premium to the biotech’s closing share price on Friday.

Sales 93

Sales Physicians Leads Patients 93

PharmaTech

FEBRUARY 6, 2023

Thermo Fisher’s sponsorship of Momentum Labs is intended to support biotech businesses in the greater Gainesville region.

52

52

European Pharmaceutical Review

FEBRUARY 5, 2024

Research predicts 2029 small molecule oncology market leaders A “big step forward” for biotech innovation In a similar move, legislation to restore immediate R&D expensing was passed in the US House of Representatives on 31 January 2024.

Food and Drug Administration 74

Food and Drug Administration Medicine Food Pharmaceutical 74

pharmaphorum

NOVEMBER 25, 2022

A B Corps company, Chiesi’s LEED Platinum certified Biotech Centre of Excellence will focus mainly on rare disease biologics – another shift in the family-business pharma’s image and action. So, the Biotech Centre of Excellence will project the group towards the future of medicine and science.

Pharmaceutical 96

Pharmaceutical Manufacturing Medicine Competition 96

pharmaphorum

DECEMBER 22, 2022

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure that is the Chiesi Group’s new €85 million Biotech Centre of Excellence, pharmaphorum web editor Nicole Raleigh spoke with Chiesi’s head of global manufacturing, Antonio Magnelli.

Manufacturing 88

Manufacturing FDA Patients 88

World of DTC Marketing

DECEMBER 10, 2021

Biogen went from being agile biotech to big pharma. Biogen’s mistakes can be traced to several factors, including hiring too many consultants who had no real business experience but perhaps their most significant failure is overestimating their success. This business can humble you in a short time.

Training 231

Training Side effects Consulting Media 231

PharmaTech

APRIL 2, 2023

A growing proportion of drugs in the development pipeline nowadays start out life at small biotech companies, rather than big pharma businesses. While this means the biotechs are taking on more risk, they will also reap greater rewards in the event of success.

Pharma 40

Pharma Management Pharmaceutical 40

World of DTC Marketing

JANUARY 7, 2021

MINUTE READ: Big pharma should take a good, hard look at small biotech companies and try to better understand how they succeed and are able to make strategic decisions faster without multi-levels of bureaucracy. She will be a real asset to their business goals. The company is lucky to have hired her.

Pharma 215

Pharma Side effects Distribution Consulting 215

pharmaphorum

NOVEMBER 10, 2022

A biotech CEO who comes from the business and investment worlds, Russell now runs Endevica, which is working on a novel therapy for cachexia, a wasting syndrome that accompanies many cancers. In the latest instalment of the pharmaphorum podcast, Editor in Chief Jonah Comstock sits down with Russell Potterfield, CEO at Endevica Pharma.

Pharma 52

Pharma Patients 52

European Pharmaceutical Review

OCTOBER 27, 2022

million people in over 127,000 businesses. For instance, small and mid-sized biotech companies invested heavily in developing vaccines. NEWS: 2021 a record year for investment in UK biotech… The post $3 trillion growth reported for biotech sector appeared first on European Pharmaceutical Review.

Pharmaceutical manufacturing 89

Pharmaceutical manufacturing Pharmaceutical Manufacturing Medical 89

World of DTC Marketing

SEPTEMBER 7, 2022

Rather than investing more in R&D, most pharma companies feel its more cost-effective to buy small biotech companies developing unique molecules that can find a market niche. Pharma companies are spending a lot of money and buying up smaller biotech companies that show any promise of developing new drugs.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

European Pharmaceutical Review

MAY 11, 2023

Delivering end-to-end expertise and solutions from research discovery to development, and diagnosis to cure, Revvity provides reagents, consumables, assays, instruments and software to customers in markets ranging from pharma and biotech , diagnostic labs, academia and government agencies. What’s ahead?

Government 72

Government Prospecting Media Marketing 72

Pharma Pathway

DECEMBER 19, 2022

Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Biotech, Microbiology, Biochemistry Students are Eligible. Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Pharmaceutical 78

Pharmaceutical Medicine 78

PM360

DECEMBER 20, 2023

How can biotech companies successfully raise funds in an environment where investment in the industry is headed for a third straight year of decline? listed on the stock exchanges, is up 13%, according to Leerink Partners’ “Navigating the Complex Terrain: Healthcare and Biotech Markets in Q3 2023” report.

Management 109

Management Marketing Healthcare Healthcare 109